VML-251 selective 5HT1D receptor partial agonist: Vanguard Medica completed a Phase IIa

Vanguard Medica, Guildford, U.K. Product: VML-251 selective 5HT1D receptor partial agonist Indication: Migraine Status: Vanguard Medica completed a Phase IIa European dose-ranging trial with its smal...